Haemonetics (HAE) Financials

Haemonetics (NYSE: HAE) shows a mixed but improving operating picture, though the latest quarter still featured a sizable net loss due to heavy expenses and financing-related pressure. Over the last several quarters, revenue has been relatively stable, margins have improved from prior-year lows, and operating cash flow has strengthened. However, the company is still carrying a meaningful debt load, recently completed an acquisition, and reported a sharp drop in net income in Q4 2026.

What stands out over the past four years:

• Revenue has held fairly steady in the low-to-mid $300 million range per quarter, suggesting the top line is not collapsing.
• Operating income improved significantly from a loss in Q4 2026’s comparison period to strong profits in several prior quarters, showing the business can generate solid operating leverage.
• Operating cash flow has generally been healthy, with recent quarters producing strong cash from operations, including $70.9 million in Q4 2026 and $93.6 million in Q3 2026.
• Cash and equivalents remain substantial at $363.4 million in Q3 2026, giving the company a decent liquidity cushion.
• Gross profit has remained relatively resilient, with gross margins generally improving versus earlier periods as cost of revenue stayed controlled.
• The company has reduced short-term debt dramatically from the elevated level seen in late 2024/early 2025, which helps near-term balance sheet pressure.
• Shares outstanding have drifted higher over time, which can dilute per-share results even when net income improves.
• The balance sheet still carries a large amount of goodwill and intangible assets, reflecting prior acquisitions and creating some non-cash asset concentration.
• Q4 2026 posted a net loss of $20.1 million and operating loss of $23.0 million, a sharp deterioration from the prior quarter’s profit.
• The latest quarter also included a very large debt repayment and continued acquisition spending, contributing to a net cash decline of $117.9 million.

Revenue trend: HAE’s revenue has been choppy but broadly stable. Quarterly revenue ranged from about $261 million in Q1 2023 to around $346 million in Q4 2026. In the most recent quarters, sales stayed in the mid-$300 million area, which suggests the company is maintaining demand even as profitability has fluctuated.

Profitability trend: Profitability improved meaningfully through 2025 and into parts of 2026, with several quarters of strong operating income and net income. That said, the latest quarter reversed course: operating expenses climbed to $221.2 million against $346.4 million of revenue, pushing the company to an operating loss. Other expense also remained negative, which widened the bottom-line loss.

Cash flow trend: The company has generally produced positive operating cash flow, which is important because it suggests the core business still generates cash even when earnings are volatile. The latest quarter’s operating cash flow of $70.9 million was solid, but investing and financing outflows were large, mainly due to acquisitions, debt repayment, and share repurchases. That made the quarter’s net change in cash negative.

Balance sheet trend: HAE’s liquidity looks adequate, but leverage remains a key watch item. Total debt is still significant, with long-term debt near $920.0 million in Q3 2026 and short-term debt around $304.7 million. Equity declined from the prior year’s levels, and accumulated losses in other comprehensive income continue to weigh on shareholders’ equity.

Bottom line: Haemonetics appears to have a business that can still generate cash and maintain revenue, but the latest quarter highlights real earnings volatility, integration risk from acquisitions, and a leveraged balance sheet. Investors may want to watch whether the Q4 2026 profit setback was temporary or the start of a broader slowdown in margin recovery.